Download MendeleyDiscovery and SAR of JTE-151: A Novel ROR gamma Inhibitor for Clinical Development.
Maeba, T., Hirata, K., Kotoku, M., Seki, N., Maeda, K., Hirashima, S., Yamanaka, H., Sakai, T., Obika, S., Hori, A., Hara, Y., Noji, S., Suwa, Y., Yokota, M., Fujioka, S., Yamaguchi, T., Katsuda, Y., Hata, T., Miyagawa, N., Arita, K., Nomura, Y., Taniguchi, T., Asahina, K., Aratsu, Y., Naka, Y., Adachi, T., Nomura, A., Akai, S., Oshida, S.I., Pai, S., Crowe, P., Bradley, E., Steensma, R., Tao, H., Fenn, M., Babine, R., Li, X., Thacher, S., Soeta, T., Ukaji, Y., Shiozaki, M.(2024) J Med Chem 67: 952-970
- PubMed: 38170624
- DOI: https://doi.org/10.1021/acs.jmedchem.3c01933
- Primary Citation of Related Structures:
8X7E - PubMed Abstract:
A number of RORγ inhibitors have been reported over the past decade. There were also several examples advancing to human clinical trials, however, none of them has reached the market yet, suggesting that there could be common obstacles for their future development. As was expected from the general homology of nuclear receptor ligands, insufficient selectivity as well as poor physicochemical properties were identified as potential risks for a RORγ program. Based on such considerations, we conducted a SAR investigation by prioritizing drug-like properties to mitigate such potential drawbacks. After an intensive SAR exploration with strong emphasis on "drug-likeness" indices, an orally available RORγ inhibitor, JTE-151, was finally generated and was advanced to a human clinical trial. The compound was confirmed to possess highly selective profiles along with good metabolic stability, and most beneficially, no serious adverse events (SAE) and good PK profiles were observed in the human clinical trial.
Organizational Affiliation:
Central Pharmaceutical Research Institute, Takatsuki Research Center, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
